After much anticipation, some leaks, and several delays, the European Commission has unveiled its latest proposal for a new regulation and directive to replace the existing provisions on me
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh